OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Acquires 500,000 Shares

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 500,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were bought at an average price of $1.48 per share, for a total transaction of $740,000.00. Following the acquisition, the chief executive officer now owns 213,036,477 shares of the company’s stock, valued at approximately $315,293,985.96. This represents a 0.24 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, December 13th, Phillip Md Et Al Frost purchased 125,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.59 per share, for a total transaction of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.56 per share, with a total value of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost purchased 199,072 shares of OPKO Health stock. The stock was acquired at an average price of $1.53 per share, for a total transaction of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.59 per share, with a total value of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The stock was acquired at an average price of $1.62 per share, for a total transaction of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The shares were acquired at an average price of $1.50 per share, with a total value of $420,274.50.

OPKO Health Trading Down 0.7 %

NASDAQ:OPK traded down $0.01 during trading hours on Wednesday, hitting $1.47. The company had a trading volume of 2,671,547 shares, compared to its average volume of 3,076,149. OPKO Health, Inc. has a 1 year low of $0.86 and a 1 year high of $1.76. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The company has a 50-day moving average of $1.54 and a 200 day moving average of $1.50. The company has a market cap of $1.00 billion, a P/E ratio of -7.74 and a beta of 1.62.

Institutional Investors Weigh In On OPKO Health

A number of hedge funds have recently modified their holdings of the company. Rubric Capital Management LP raised its stake in OPKO Health by 9.6% during the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after purchasing an additional 4,284,336 shares during the period. Assenagon Asset Management S.A. raised its position in shares of OPKO Health by 142.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock valued at $2,227,000 after buying an additional 876,272 shares during the period. PFG Investments LLC lifted its holdings in OPKO Health by 10.4% in the third quarter. PFG Investments LLC now owns 1,061,090 shares of the biotechnology company’s stock valued at $1,581,000 after acquiring an additional 100,125 shares during the last quarter. Clearline Capital LP purchased a new position in OPKO Health in the third quarter worth approximately $1,083,000. Finally, Barclays PLC increased its stake in OPKO Health by 154.5% during the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after acquiring an additional 329,870 shares during the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on OPK shares. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research report on Friday, November 8th. StockNews.com cut OPKO Health from a “hold” rating to a “sell” rating in a research report on Wednesday. Piper Sandler reaffirmed an “overweight” rating and set a $3.00 price objective on shares of OPKO Health in a research note on Tuesday, September 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research note on Wednesday, January 8th.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.